NYSE:OGEN Oragenics (OGEN) Stock Price, News & Analysis → Boost your retirement with these AI payouts (From InvestorPlace) (Ad) Free OGEN Stock Alerts $2.95 -0.12 (-3.91%) (As of 10:55 AM ET) Add Compare Share Share Today's Range$2.76▼$3.1050-Day Range$1.01▼$3.0952-Week Range$1.00▼$7.74Volume83,346 shsAverage Volume105,200 shsMarket Capitalization$13.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Oragenics alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Oragenics Stock (NYSE:OGEN)Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More OGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OGEN Stock News HeadlinesMay 18 at 3:40 AM | americanbankingnews.comOragenics (NYSE:OGEN) Research Coverage Started at StockNews.comMay 17, 2024 | globenewswire.comOragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineMay 16, 2024 | msn.comOragenics climbs 9% amid Phase 2 study, business updatesMay 16, 2024 | finance.yahoo.comOragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialMay 16, 2024 | investorplace.comOGEN Stock Earnings: Oragenics Reported Results for Q1 2024May 11, 2024 | finance.yahoo.comOragenics, Inc. (OGEN)May 7, 2024 | msn.comOragenics partners with Avance Clinical for Phase 2 concussion studyMay 7, 2024 | finance.yahoo.comOragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaApril 27, 2024 | finance.yahoo.comOragenics, Inc. (OGEN) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | finance.yahoo.comOdyssey Health, Inc. (ODYY)April 19, 2024 | businesswire.comOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsApril 17, 2024 | money.usnews.comOragenics IncApril 16, 2024 | ca.finance.yahoo.comOragenics, Inc. (OGEN) Latest Stock News & Headlines - Yahoo FinanceApril 1, 2024 | finance.yahoo.comOragenics, Inc. Files 10K and Provides Company UpdateMarch 18, 2024 | markets.businessinsider.comOragenics Appoints Kelly As Chief Medical OfficerMarch 17, 2024 | finance.yahoo.com15 Highest Quality Probiotics For Gut HealthMarch 5, 2024 | businesswire.comOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionMarch 1, 2024 | businesswire.comOragenics Announces Closing of Public OfferingMarch 1, 2024 | uk.investing.comOragenics announces public stock offeringFebruary 28, 2024 | investorplace.comWhy Is Oragenics (OGEN) Stock Down 45% Today?February 27, 2024 | markets.businessinsider.comOragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock PlungesFebruary 27, 2024 | businesswire.comOragenics Announces Pricing of Public OfferingFebruary 27, 2024 | marketwatch.comOragenics Shares Fall After Proposed Public OfferingFebruary 27, 2024 | businesswire.comOragenics Announces Proposed Public OfferingFebruary 12, 2024 | marketwatch.comOragenics CEO Murphy Leaves, President Redmond Named Interim ReplacementSee More Headlines Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:OGEN Previous SymbolNYSE:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,660,000.00 Net MarginsN/A Pretax Margin-96,485.71% Return on Equity-615.16% Return on Assets-325.98% Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio2.69 Sales & Book Value Annual Sales$40,000.00 Price / Sales346.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book5.07Miscellaneous Outstanding Shares4,481,000Free Float3,379,000Market Cap$13.85 million OptionableN/A Beta0.40 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Charles L. Pope CPA (Age 72)Executive Chairman Comp: $112.5kMr. Joseph Michael Redmond (Age 63)President & Interim Principal Executive Officer Ms. Janet Huffman (Age 52)CFO, Secretary & Treasurer Comp: $314.9kDr. James P. Kelly M.A.M.D., Chief Medical Officer & Member of Scientific AdvisorKey CompetitorseFFECTOR TherapeuticsNASDAQ:EFTRVirios TherapeuticsNASDAQ:VIRICan-Fite BioPharmaNYSE:CANFBionomicsNASDAQ:BNOXVaxxinityNASDAQ:VAXXView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 22,675 shares on 5/20/2024Ownership: 0.506%Fred TellingSold 3,500 sharesTotal: $12,495.00 ($3.57/share)View All Insider TransactionsView All Institutional Transactions OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed in 2024? Oragenics' stock was trading at $6.1382 at the start of the year. Since then, OGEN shares have decreased by 51.9% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSE:OGEN) posted its quarterly earnings results on Friday, March, 29th. The company reported ($5.48) EPS for the quarter. When did Oragenics' stock split? Shares of Oragenics reverse split on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ), MFA Financial (MFA) and Who are Oragenics' major shareholders? Oragenics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.51%). Insiders that own company stock include Fred Telling, Michael O'keefe Sullivan and Robert C Koski. View institutional ownership trends. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:OGEN) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.